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ABSTRACT Dynamin-related protein (Drp) 1 is a key
regulator of mitochondrial fission and is composed of
GTP-binding, Middle, insert B, and C-terminal GTPase
effector (GED) domains. Drp1 associates with mitochon-
drial fission sites and promotes membrane constriction
through its intrinsic GTPase activity. Themechanisms that
regulate Drp1 activity remain poorly understood but are
likely to involve reversible post-translational modifica-
tions, such as conjugation of small ubiquitin-like modifier
(SUMO) proteins. Through a detailed analysis, we find
that Drp1 interacts with the SUMO-conjugating enzyme
Ubc9 via multiple regions and demonstrate that Drp1
is a direct target of SUMO modification by all three
SUMO isoforms. While Drp1 does not harbor con-
sensus SUMOylation sequences, our analysis identi-
fied2 clusters of lysine residues within the B domain
that serve as noncanonical conjugation sites. Al-
though initial analysis indicates that mitochondrial
recruitment of ectopically expressed Drp1 in response
to staurosporine is unaffected by loss of SUMOylation,
we find that Drp1 SUMOylation is enhanced in the
context of the K38A mutation. This dominant-negative
mutant, which is deficient in GTP binding and hydro-
lysis, does not associate with mitochondria and pre-
vents normal mitochondrial fission. This finding sug-
gests that SUMOylation of Drp1 is linked to its activity
cycle and is influenced by Drp1 localization.—Figueroa-
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Kolliker first described mitochondria as granules
over 150 years ago in 1857, but it is only within the past
several decades that the important role of mitochon-
drial malfunction in disease has been appreciated.
Mitochondria are highly dynamic organelles, and their
proper function relies on orchestrated fusion and
fission events (1).
An evolutionary conserved set of molecules compris-
ing members of the dynamin family of proteins regu-
lates the balance between mitochondrial fusion and
fission. In mammalian cells, the mitochondrial outer
membrane proteins Mitofusin 1 and 2 (Mfn1, Mfn2)
and inner mitochondrial membrane-associated protein
optic atrophy protein (OPA) 1 regulate fusion (2, 3).
Conversely, the Fission1 protein (Fis1) acts as a recep-
tor at the outer mitochondrial membrane for the
dynamin-related protein (Drp1) (4–6).
Mitochondrial dynamics have a significant effect in
the development of mitochondrial diseases, particularly
for muscle and neuronal cells (7–11). Mutations in
OPA1 and Mfn2 lead to autosomal dominant optic
atrophy type 1 and two autosomal dominant forms of
Charcot-Marie-Tooth (CMT) neuropathy, respectively
(12–14). Recently, a mutation in Drp1 was found to
lead to phenotypic characteristics overlapping those of
CMT and optic atrophy but with a fulminate prenatal
onset and death shortly after birth (15).
Drp1 is predominantly a cytoplasmic protein com-
posed of an N-terminal GTPase domain, which binds
and hydrolyzes GTP, followed by a Middle domain
important for multimerization, a variable B or coiled-
coiled domain, and a GTPase-effector domain (GED)
(16). Drp1 associates with mitochondrial fission sites
upon oligomerization. Powered by its GTPase activity, it
provides the driving force for mitochondrial mem-
brane constriction in a manner similar to the role of
dynamin in endocytosis (17–19). Drp1 also facilitates
apoptotic mitochondrial fission, mainly by promoting
mitochondrial outer membrane permeabilization
(MOMP) induced by members of the Bcl-2 proapop-
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totic family of proteins (Bax/Bak) prior to physical
fragmentation of mitochondria (20–22).
Although it is widely accepted that Drp1 plays a key
role in driving mitochondrial fission, the molecular
regulators of Drp1 that enable it to perform this task
during different biological activities are only beginning to
be revealed. Recent data indicate that Drp1 is the target
for multiple post-translational modifications, such as
phosphorylation, ubiquitination, S-nitrosylation, and the
conjugation of small ubiquitin-like modifier proteins, or
SUMOylation (23–32). These modifications are known to
modulate protein-protein interactions, subcellular local-
ization, protein degradation, and activation of signaling
pathways. Such modifications may work in cooperation or
antagonistically in response to environmental cues (33).
SUMOylation is a conserved post-translational modi-
fication process that uses a distinct but enzymologically
parallel pathway to ubiquitination. SUMOylation, how-
ever, exerts unique functional roles. Four mammalian
SUMO isoforms have been identified (SUMO1, 2, 3,
and 4). SUMO2 and SUMO3 are closely related,
whereas SUMO1 shares 48% identity to either SUMO2
or SUMO3 (34, 35). A fourth isoform closely related to
SUMO2/3 (36) harbors a Pro residue at position 90
that prevents initial processing by known SUMO pro-
tease enzymes and subsequent conjugation (37).
Whether this member functions exclusively through
noncovalent interactions remains to be determined.
SUMO conjugation involves specific E1-activating
(SAE1/SAE2) and E2-conjugating (Ubc9) enzymes.
Ubc9 catalyzes the formation of an isopeptide bond
between the carboxyl terminus of SUMO and the
ε-amino group of the target lysine (38). This step is
facilitated by SUMO E3 ligases, such as RanBP2, and
members of the protein inhibitor of activated STAT
(PIAS) family (39–41). SUMOylation is reversible, and
specific isopeptidases release the SUMO moiety (42).
The functional consequences of SUMOylation are target
specific, but in many cases the effects of SUMO depend on
a distinct effector surface (43) that recognizes SUMO-inter-
acting motifs in target proteins (44).
Although the effects of SUMO modification have
been best characterized for nuclear proteins, such as
sequence-specific transcription factors, recent evidence
indicates that cytosolic as well as integral membrane
proteins (45) are SUMOylated and that this modifica-
tion exerts important regulatory roles. How this modi-
fication influences mitochondrial function, however,
remains largely unknown. In this regard, despite the
identification of Ubc9 and SUMO1 as Drp1-interacting
proteins in a yeast 2-hybrid screen (28) and subsequent
data implicating the SUMO protease SENP5 and the
mitochondrial-anchored protein ligase (MAPL) in mi-
tochondrial dynamics (31, 32), the exact targets of the
SUMOylation machinery in this context have not been
fully established. While multiple Drp1 species of various
molecular masses have been proposed to be SUMO1-
modified forms of Drp1 (28, 31), which of these
unambiguously represent SUMO conjugated forms of
Drp1 has not been resolved. In addition, whether other
SUMO isoforms are involved in this process is un-
known. Clearly, a specific assessment of the effect of
SUMOylation on the function of Drp1 is hampered by
the absence of knowledge of the sites of modification,
especially since sequence analysis indicates that Drp1
does not contain canonical SUMO conjugation sites.
To address these issues, we have undertaken a system-
atic examination of Drp1 SUMOylation. Our results
provide important molecular tools to investigate di-
rectly the biological significance of Drp1 SUMOylation
in mitochondrial function.
MATERIALS AND METHODS
Plasmids and antibodies
Human pcDNA3-Drp1 wild-type (WT) and dominant nega-
tive (DN) mutant pcDNA3-Drp1 K38A (19, 22) were obtained
from Dr. Richard J. Youle (National Institutes of Health,
Bethesda, MD, USA) and used as templates to generate
pcDNA3 vectors driving the expression of N-terminal V5 and
hexahistidine-tagged WT Drp1 and its derivatives as well as
the yeast 2-hybrid constructs. Eukaryotic expression vectors
(pGW1) for Myc-and HA-epitope-tagged Drp1 have been
described previously (16). Expression vectors for N-terminal
HA-tagged SUMO isoforms are pcDNA3 based and have been
described previously (43). Similarly, human SUMO1 and
ubiquitin cDNAs were cloned into the EcoRI site of pGW1
with an N-terminal Myc-epitope tag. pcDNA3-Ubc9 was a kind
gift of Dr. Kim Orth (University of Texas Southwestern
Medical Center, Dallas, TX, USA). pcDNA3-V5-Ubc9 was
generated by amplification of the Ubc9 sequence by RT-PCR
from the human neuroblastoma cell line SH-EP using the
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) and
subcloned into a pcDNA3 derivative bearing an N-terminal
V5 tag. The CS2 plasmid was a kind gift of Dr. David Turner
(University of Michigan, Ann Arbor, MI, USA). Mutations
were introduced into all vectors using the QuikChange
method (Stratagene, La Jolla, CA, USA).
The pLex and VP16 yeast expression vectors were kindly
provided by Dr. Anne B. Vojtek (University of Michigan) and
were used to generate VP16-Ubc9, pLex-Drp1 full-length,
pLex-Drp GTPase domain (aa 1–225), pLex-Drp1 Middle
domain (aa 227–521), pLex-Drp B domain (aa 502–626),
pLex-Drp GED domain (aa 627–736), and pLex-Drp No
GTPase domain (aa 227–736) vectors. All constructs were
confirmed by sequencing.
Sources of antibodies were as follows: anti-Drp1, mouse
monoclonal H00010059 (Abnova, Walnut, CA, USA); anti-
HA, mouse monoclonal 12CA5 (Abcam, Cambridge, MA,
USA), rabbit polyclonal HA.11 (Covance, Princeton, NJ,
USA); anti-GAPDH, mouse monoclonal (Chemicon, Te-
mecula, CA, USA); anti-Myc, monoclonal 9E10 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA); anti-HSP60, mouse
monoclonal (Sigma-Aldrich, St. Louis, MO, USA). Secondary
antibodies were horseradish peroxidase-conjugated sheep
anti-mouse (Pierce, Rockford, IL, USA) and goat anti-rabbit
(Santa Cruz Biotechnology).
Cell culture and transient transfections
Human embryonic kidney (HEK)-293 cells were grown at
37°C in 10% CO2 in Dulbecco’s modified Eagle’s medium
(DMEM; Cellgro, Manassas, VA, USA), supplemented with
10% fetal bovine serum (Hyclone, Logan, UT, USA), penicil-
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lin, and streptomycin. Transient transfections were per-
formed using LipofectAmine 2000 reagent (Invitrogen, Carls-
bad, CA, USA) with a total of 3 g of DNA: 0.5 g of Drp1,
SUMO, and Ubc9 expression plasmids, 1.5 g empty vector.
Cos7 cell culture and transfections were as described previ-
ously (16).
In vivo SUMOylation
Procedures using the His-tagged Drp1 constructs were adapted
from Benson et al. (45). Briefly, HEK-293 cells were plated at
3.5  105 cells/35-mm dish and transiently transfected 24 h
later. Transfection medium was removed and replaced 6 h
later with fresh medium. Cells were lysed 22 h after trans-
fection in CHAPS (3-[(3-cholamidopropyl) dimethylammo-
nio]-1-propanesulfonate) lysis buffer [0.5 mM NaCl, 25 mM
imidazole, 45 mM Na2HPO4, 5 mM NaH2PO4, and 1%
CHAPS,  20 mM N-ethylmaleimide (NEM), pH 8.0] supple-
mented with aprotinin, phenylmethanosulfonyl fluoride
(PMSF), leupeptin, and Na2VO4. Cell lysates were precleared
by centrifugation. Protein extracts (45 l) were mixed with
2 sample buffer (100 mM Tris, pH 6.8; 4% SDS; 10%
glycerol; and 0.015% bromphenol blue). The remainder of
the extracts was incubated with nickel-agarose (Ni2) beads
(Qiagen) for 1 h at 4°C. Beads were washed 3 with CHAPS
wash buffer 1 (0.4 mM NaCl, 25 mM imidazole, 17.6 mM
Na2HPO4, 32.4 mM NaH2PO4, and 0.1% CHAPS, pH 6.75);
2 with CHAPS wash buffer 2 (0.150 mM NaCl, 17.6 mM
Na2HPO4, 32.4 mM NaH2PO4, 0.1% CHAPS, and 8M urea,
pH 6.75); and 3 with buffer 3 (50 mM NaCl, 45 mM
Na2HPO4, 5 mM NaH2PO4, and 0.1% CHAPS, pH 8.0). Beads
were then resuspended in 70 l 3 EDTA sample buffer [150
mM Tris, pH 6.8; 10 mM EDTA; 6% SDS; 15% glycerol;
0.0225% bromphenol blue; and 20 mM -mercaptoethanol
(-ME)]. The eluates were incubated at 50°C for 20 min, and
the extracts were boiled for 3 min. Samples were centrifuged
prior to loading onto 7.5 or 12.5% SDS-polyacrylamide gels.
Samples were processed for Western blot analysis and probed
with the indicated antibodies.
For assays using HA- and Myc-tagged Drp1 forms, SUMOylation
was assessed in immunoprecipitates. Briefly, extracts from COS7
cells cotransfected with HA-Drp1 and Myc-SUMO1 (WT or
mutant, as indicated), or else transfected with Myc-SUMO1
alone, were immunoprecipitated using anti-HA antibodies, as
described previously (16). Myc-Drp1 was expressed alone where
indicated. Protein samples were resolved by SDS-PAGE, then
transferred to nitrocellulose membranes and immunoblotted
with the indicated antibodies, as described previously (16).
Yeast 2-hybrid assays
Transformation of the Saccharomyces cerevisiae reporter strain
L40 was as described previously (46). Briefly, L40 was cotrans-
formed with vectors expressing fusion proteins of LexA DNA
binding domain (LexA) to full-length Drp1 or Drp1 deletions
and vectors expressing Ubc9 as a fusion protein to the VP16
acidic activation domain (VP16). Cotransformed colonies
were grown in medium lacking tryptophan and leucine
(Trp/Leu), and serial dilutions were plated. Recovery of
cells bearing both plasmids was confirmed by growth on
Trp/Leu plates. The interaction between proteins was
assessed by growth on minimal medium plates also lacking
histidine (Trp/Leu/His), indicating the activation of the
Lex operator driven by the HIS reporter gene. The L40
strain was obtained from Dr. Anne B. Vojtek (University of
Michigan).
Isolation of mitochondria
HeLa cells were transfected with WT or mutant Myc-Drp1
were either left untreated or else treated with 1 M stauro-
sporine (Sigma-Aldrich) for 8 h in the presence of 100 M
zVAD-fmk (Calbiochem, San Diego, CA, USA). Mitochondria
were isolated intact from HeLa cells by sucrose density
gradient centrifugation and subjected to SDS-polyacrylamide
gel electrophoresis and immunoblotting, as described previ-
ously (47, 48).
RESULTS
Ubc9 forms a bipartite interaction with two different
domains of Drp1
Recent reports indicate that post-translational modifi-
cations of Drp1, such as phosphorylation, ubiquitina-
tion, and SUMOylation, are important for proper mi-
tochondrial morphology and function (49). The
conjugation of SUMO to target proteins is carried out
by the E2 enzyme Ubc9 and involves as a prerequisite
the recruitment of Ubc9 to the modified protein (50,
51). We therefore examined the interaction between
Ubc9 and Drp1. We expressed various domains of Drp1
singly or in combination as pLex fusion proteins and
tested their interaction with VP16-Ubc9 in the yeast
2-hybrid system (Fig. 1). Our results indicate that Ubc9
binds to two distinct regions of Drp1 mapped to the
GTPase and B domains. Interestingly, in the absence of
the GTPase domain, the GED and Middle domains
appear to interfere with the binding of Ubc9 to the B
domain (Fig. 1). This indicates that the architecture of
Drp1 is important for its interaction with Ubc9. Consis-
tent with Drp1 serving as a target of SUMOylation, we
Figure 1. Ubc9 interacts with the GTPase and B domains of
Drp1 in the yeast 2-hybrid assay. L40 yeast cells were cotrans-
formed with vectors expressing fusion proteins of LexA DNA
binding domain (LexA) (bait) with full-length Drp1 (aa
1–736), GTPase (GTP) domain (aa 1–225), Middle domain
(aa 227–521), no-GTPase domain (aa 227–736), B domain
(aa 502–626), or GTPase-effector (GED) domain (aa 627–
736) and vectors expressing Ubc9 as a fusion protein with the
VP16 activation domain (VP16) (prey). Cotransformed colo-
nies were grown on Trp/Leu medium; serial yeast dilutions
were plated. Expression of both plasmids is confirmed by
growth inTrp/Leu plates; interaction between proteins was
assessed by growth of yeast on minimal medium plates
(Trp/Leu/His),indicating activation of the HIS reporter.
None of the baits conferred histidine auxotrophy in the
absence of the Ubc9 prey (data not shown).
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also detect an interaction between Drp1 and conjuga-
tion competent forms of SUMO1, -2, and -3, although
this interaction is substantially weaker (data not
shown).
Drp1 is a target of SUMOylation
Recent data suggest that Drp1 is a target of SUMO1
modification (28), but the identity of SUMO conju-
gated forms as well as the SUMO isoform preference
for Drp1 modification has not been examined. To this
end, we have applied a validated cell culture expression
approach that takes advantage of the covalent conjuga-
tion of SUMO and purification under denaturing con-
ditions to examine under high-stringency conditions
the SUMOylation of Drp1. As seen in Fig. 2A (Ni2
eluate panels, arrowheads), analysis of hexahistidine-
tagged Drp1 preparations isolated under denaturing
conditions from HEK-293T cells coexpressing SUMO
conjugating enzyme Ubc9 and each of the 3 major
SUMO isoforms (SUMO1, -2, and -3) revealed that in
addition to unmodified Drp1 (asterisk), a slower mi-
grating Drp1 immunoreactive doublet is detected in
cells expressing SUMO3 (arrowheads). On extended
exposure, similar species are detected in SUMO2-ex-
pressing cells. Drp1-SUMO1 conjugates were difficult
to identify under these conditions. The slower-migrat-
ing Drp1 species, with an apparent molecular mass of
100 kDa, are also immunoreactive toward the HA
epitope present in the SUMO isoforms, consistent with
their identity as SUMO-modified forms of Drp1.
Interestingly, we do observe Drp1 immunoreactive
species migrating at significantly higher positions in the
gel (Fig. 2A, open circle). Such species, however, are
not immunoreactive for the HA epitope (Fig. 2A, lanes
5–7) and are SUMO independent (Fig. 2A, lane 1).
Thus, these high-molecular-mass species are unlikely to
be SUMO modified. Whether these species correspond
to the high-molecular-mass forms Harder et al. (28)
interpreted as Drp1 modified by poly-SUMO1 chains
remains to be determined. Given that Drp1 likely
self-assembles into large multimeric complexes in vivo,
as does dynamin, these apparent high-molecular-
mass species may represent entangled SDS-resistant
oligomers.
To further validate the identification of the slow-
migrating 100-kDa doublets as Drp1-SUMO conju-
gates, we omitted the alkylating agent NEM during
extract preparation. NEM is an agent that irreversibly
inhibits SUMO proteases by alkylating a catalytic cys-
teine in their active site. As seen in the HA blot of
Figure 2. Drp1 is modified by SUMO1, SUMO2, and SUMO3.
A) HEK-293 cells were transfected transiently with expression
vectors for pcDNA3-Ubc9 and/or pcDNA3-HA-SUMO1, pcDNA3-
HA-SUMO2, or pcDNA3-HA-SUMO3 and/or pcDNA3-V5-His-
Drp1. Cells were lysed in the presence of 20 mM NEM, and
His-Drp1 was isolated via Ni2 chelate chromatography un-
der denaturing conditions. Proteins from Ni2 eluates and
extracts were visualized by Western immunoblot (IB) analysis
using antibodies against Drp1, HA-epitope, and GAPDH.
Migrations of unmodified and SUMO-conjugated forms of
Drp1 are indicated by asterisk and arrowheads, respectively.
Open circle indicates larger apparent molecular mass Drp1
forms likely representing entangled SDS-resistant oligomers.
B) SUMO modification of Drp1 is Ubc9 and SUMO3 depen-
dent and NEM sensitive. HEK-293 cells transiently transfected
with pcDNA3-Ubc9 and pcDNA3-HA-SUMO3 and/or
pcDNA3-V5-His-Drp1 were lysed in the presence or absence
of 20 mM NEM and analyzed as in A. C) Cells were cotrans-
fected with HA-Drp1 and Myc-SUMO1, or else transfected
with Myc-SUMO1 alone, and cell lysates were immunoprecipi-
tated using anti-HA antibodies as indicated (-HA IP), then
immunoblotted using anti-Myc antibodies. Arrowheads indi-
cate SUMO-modified Drp1 forms. Myc-Drp1 expression (as-
terisk) identifies the size of unmodified Drp1, as it is identical
in size to HA-Drp1. D) Cells were cotransfected with HA-Drp1
(aa 326–736) and Myc-SUMO1, and extracts were immuno-
precipitated with anti-HA antibodies and then immunoblot-
ted for Myc as in C. Arrowheads indicate SUMO-modified
Drp1 (aa 326–736) forms. Myc-Drp1 (aa 326–736) expression
(asterisk) identifies the size of unmodified Drp1, which is
identical in size to HA-Drp1 (aa 326–736). Migrations of
molecular mass standards (kDa) are at left.
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cellular extracts (Fig. 2B, extracts), omission of this
reagent leads to loss of most SUMO conjugates. Con-
sistent with the assignment as SUMOylated Drp1, the
slow migrating Drp1 and HA immunoreactive species
are also lost in the absence of NEM despite the appar-
ent higher recovery of Drp1 under these conditions
(Fig. 2B, eluates).
Notably, although the above data indicate that
SUMO3 conjugates are more readily detected, this is
likely a simple reflection of the relative expression and
overall conjugation of these tagged SUMO isoforms, as
revealed by analysis of the cell extracts (Fig. 2A, ex-
tracts). Using an alternative approach in Cos7 cells,
where Myc-epitope tagged SUMO1 conjugates are
readily detected (Fig. 2C), we also recover the slower
migrating doublet by immunoprecipitating HA-Drp1
from cells overexpressing Myc-SUMO1 (Fig. 2C). Nota-
bly, analysis of an N-terminally truncated form of Drp1
in this assay indicates that the slow-migrating SUMO-
containing species correspond to SUMO1–Drp1 conju-
gates, since their apparent molecular mass is appropri-
ately reduced in the case of the truncated Drp1 (326–
736) form (Fig. 2D). Furthermore, the data indicate
that the N-terminal GTPase region is dispensable for
SUMO conjugation to Drp1. Taken together, our re-
sults indicate that Drp1 is a target of SUMO modifica-
tion by all three conjugatable SUMO isoforms and that
this modification preferentially occurs in the C-termi-
nal half of the protein.
Drp1 is SUMO-modified at two lysine clusters located
in the B domain
The above data indicate that an N-terminally truncated
Drp1 form lacking the GTPase and part of the Middle
domain is still SUMO-modified (Fig. 2D). Analysis of
the Drp1 sequence and of this fragment indicates no
clear instances of the SUMOylation consensus se-
quence, suggesting that the modification may occur at
nonconsensus sites. In an effort to identify such modi-
fication sites, we performed a systematic mutational
analysis. We replaced individually all 25 lysine residues
present within the region comprising residues 326–736
and examined the SUMOylation of the resulting full-
length protein. Remarkably, the slow-migrating doublet
remains clearly present in all mutants (Fig. 3). This
finding suggests that Drp1 SUMOylation likely occurs
at multiple sites, and given their noncanonical nature,
significant redundancy may be present.
We next took a group-mutational approach to iden-
tify lysines required for SUMO modification (Fig. 4A,
B). We found that joint substitution of 13 lysine resi-
dues to arginines within this region (13 KR) led to a
complete elimination of the doublet of SUMO conju-
gated species (Fig. 4B). Mutation of the 7 N-terminal
lysines (7 KR) resulted in loss of the upper SUMO-
conjugated species, while replacement of the 6 C-
terminal lysines (6 KR) led to the corresponding loss of
the lower one (Fig. 4B). This suggests that the two
modified forms likely represent Drp1 species modified
at two different sets of lysines within this region, with
the N-terminal ones responsible for the upper species
and the C-terminal ones for the lower species.
Human Drp1 has three different splice variants (52)
comprising the full-length 736-aa protein (variant 1) as
well as forms lacking 27 (variant 2) or 37 (variant 3)
amino acid residues in the B domain (Fig. 4A). Since
four of the lysines within the 7 KR segment are within
the differentially spliced region, we compared the
SUMO modification of the three different variants. As
shown in Fig. 4C, the doublet is present only in variant
1, which suggests that lysines necessary for the genera-
tion of the upper SUMO-conjugated species in the
doublet are contained within the alternatively spliced
region. Indeed, analysis of a mutant Drp1 (var. 1) in
which the 4 lysines within the alternatively spliced
region are replaced by arginines (Spl KR) indicated a
loss of the upper modified species (Fig. 4D). To exam-
ine the contribution of each residue, we systematically
reintroduced individual lysines in the context of the Spl
KR mutant. As seen in Fig. 4D, reintroduction of any of
the 4 lysines leads to a restoration of the upper modi-
fied species, indicating that lysines 532, 535, 558, and
568 can function as SUMO-acceptor residues within
this region.
We followed a similar approach to identify the lysines
within the 6 KR region that contribute to the genera-
tion of the lower modified species. We performed the
analysis using Drp1 variant 3, which lacks the upper
form. As expected, replacement of all six lysine residues
in the context of variant 3 led to an essentially complete
loss of SUMOylation. Reintroduction of any of the four
N-terminal lysines (K594, K597, K606, K608) led to a
Figure 3. Mutational analysis of potential SUMO-acceptor
lysines. Schematic diagram of Drp1 domain organization (top
panel); vertical lines identify lysine residues within aa 326–
736 mutated to arginines in the bottom panels. Cells were
cotransfected with Myc-SUMO1 and WT HA-Drp1 (aa 1–736;
splice variant 1) or the indicated Drp1 mutants (single amino
acid letter code). Extracts were immunoprecipitated with
anti-HA antibodies and then immunoblotted for Myc. Arrow-
heads indicate SUMO-modified Drp1. Myc-Drp1 expression
(asterisk) identifies the size of unmodified HA-Drp1. Migra-
tions of molecular mass standards (kDa) are at left.
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partial restoration of SUMOylation, whereas reintro-
duction of either of the two C-terminal ones did not
(Fig. 4E). Each of these variants was expressed at
comparable levels, as revealed by the HA immunoblot
of cellular extracts (Fig. 4E, bottom). Since reintroduc-
tion of single lysine residues did not fully restore
SUMOylation to the level observed for variant 3, the
data suggest that all four lysines likely contribute to the
lower modified species. Consistent with this analysis,
block substitution of these 4 lysines in variant 3 led to a
complete loss of Drp1 SUMOylation (Fig. 4F). Since in
some cases, lysine residues are sites for both SUMOyla-
tion and ubiquitination, we also examined the ubiquiti-
nation of the SUMOylation-deficient Drp1 (variant1)
13 KR mutant. As shown in Fig. 4G, it appears that the
lysine residues within Drp1 involved in SUMO modifi-
cation are dispensable for ubiquitination, since the 13
KR mutant is ubiquitinated to levels comparable to WT
Drp1. Taken together, the mapping analysis clearly
indicates that Drp1 SUMOylation occurs mainly at two
lysine clusters within the B domain. Given the nonca-
nonical nature of these sites, it is likely that the ability of
Ubc9 to interact with this region (Fig. 1) allows the
modification of redundant lysines without strict adher-
ence to the consensus. These sites, however, are dis-
pensable for ubiquitination of Drp1.
SUMOylation-deficient Drp1 is recruited to
mitochondria in response to staurosporine
Our mapping of the major SUMOylation sites in Drp1
provides the opportunity to begin exploring the role of
this modification in Drp1 function. Mitochondrial recruit-
ment is central to the role of Drp1 in normal mitochon-
drial fission and apoptotic MOMP in response to pro-
apoptotic agents such as staurosporine (22). Analysis of
cells overexpressing WT or SUMOylation deficient (4 KR)
Myc-Drp1 (var. 3) revealed that the basal and staurospo-
rine-stimulated recruitment of ectopically expressed Drp1
to mitochondria is not affected by loss of SUMO modifi-
cation (Fig. 5). The data, therefore, indicate that prevent-
ing SUMO modification of exogenous Drp1 does not lead
to an overall dominant-negative effect on recruitment of
Drp1 to the mitochondria.
Enhanced SUMOylation of a dominant-negative form
of Drp1
The GTPase activity of Drp1 is essential for its ability to
promote mitochondrial fission (19). The SUMO mod-
Figure 4. Noncanonical SUMOylation sites are present within
the B domain of Drp1. A) Schematic diagram of Drp1;
vertical lines identify lysine residues mutated to arginines in
the other panels. In the 5 constructs at bottom, indicated Lys
residues (red) were converted to Arg residues, and constructs
were named as shown. B) Cells were cotransfected with
Myc-SUMO1 and WT HA-Drp1 (aa 1–736; splice variant 1) or
the indicated Drp1 mutants shown in A. Extracts were immu-
noprecipitated with anti-HA antibodies and then immuno-
blotted for Myc. Arrowheads indicate SUMO-modified Drp1,
as in subsequent panels. Myc-Drp1 expression (asterisk) iden-
tifies size of unmodified HA-Drp1, as in subsequent panels.
C) Cells were transfected and analyzed as in B, examining the
3 splice variants of WT Drp1. D) Cells were transfected and
analyzed as in B, with indicated mutated residues in Drp1 Spl
KR individually returned to the Lys residues found in the WT
form. E) Cells were transfected and analyzed as in D, though
HA-Drp1 was the variant 3 form, and the residues were
reverted from the 6 KR mutant. Bottom panel: total cell lysates
were immunoblotted for HA to demonstrate equal expression
of all Drp1 forms. F) Cells were cotransfected with Myc-
SUMO1 and either WT or 4 KR mutant HA-Drp1 (splice
variant 3). Extracts were immunoprecipitated with anti-HA
antibodies and then immunoblotted for Myc (top panel) or
HA (bottom panel). G) Cells were cotransfected with Myc-
ubiquitin and either WT or 13 KR mutant HA-Drp1 (splice
variant 1). Extracts were immunoprecipitated with anti-HA
antibodies and then immunoblotted for Myc.
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ification of Drp1 could therefore influence Drp1 func-
tion through an association with its GTPase cycle.
Within the GTPase domain of Drp1, the conserved P
loop lysine at position 38, which in dynamin forms
hydrogen bonds with residues from switch II (53), plays
a critical role in Drp1 function. An alanine substitution
at this position severely hampers Drp1 function and
confers to the protein a dominant-negative behavior.
The resulting block in fission leads to unopposed
mitochondrial fusion (19). We therefore examined the
effect of the K38A substitution on Drp1 SUMOylation.
Notably, as shown in Fig. 6, we consistently observed an
increase in SUMO3 modification of the dominant-
negative K38A mutant compared to WT Drp1, reveal-
ing that the SUMOylation of Drp1 is linked to its
activity cycle.
DISCUSSION
The dynamin-related protein, Drp1, is a fission protein
and a key molecular regulator of mitochondria and
peroxisome function (54–56). Drp1 is post-translation-
ally modified, and some of these modifications are
thought to regulate the ability of Drp1 to promote
fission (49). Although the SUMO family of proteins is
widely distributed (57), the subcellular localizations are
distinct. SUMO1 is localized at the nuclear membrane
and nuclear bodies, SUMO2 is mainly cytoplasmic, and
SUMO3 is mostly found in the nuclear bodies (58, 59).
Although this finding suggests individual forms may
perform specific biological roles, a significant overlap
exists, since knockout of SUMO1 in mice is not lethal
(60). The members of the SUMO protein family are
also regulated distinctively by post-translational modifi-
cations (61). SUMO2 and SUMO3 form multimers
in vitro and in vivo due to internal SUMOylation
consensus sites. SUMO1 is incorporated into these
chains, but the lack of SUMOylation sites is thought to
prevent SUMO1-chain formation in vivo, although such
chains are readily formed in vitro (59, 61, 62). Drp1 has
been reported to be modified by SUMO1 in an “all-or-
none” manner, and very high molecular mass forms
were interpreted as Drp1-harboring covalent SUMO1
chains (28). However, we have clearly demonstrated
that Drp1 is a target of SUMOylation by all three SUMO
isoforms but without evidence of large chain formation,
since these species migrate as a 100-kDa doublet.
With regard to the different SUMO isoforms, it is
important to note that oxidative stress generally leads
to significantly enhanced SUMO2/3 modification.
Given the central role of mitochondria in pathological
oxidative stress, it will be interesting to examine
whether SUMO2/3 modification of Drp1 or other
mitochondrial components plays a role in the adaptive
and maladaptive mitochondrial response to oxidative
stress.
The dynamin family of proteins is characterized by
distinct functional domains, including a GTPase do-
main, a Middle domain, and an effector (or GED)
domain. The B domain in Drp1, which is absent in
dynamin, is the most variable region through evolution,
and no specific role has been assigned to this domain.
Here we show that the E2 SUMO-conjugating enzyme
Ubc9 binds to the B domain of Drp1 in a yeast 2-hybrid
assay (Fig. 1). Recruitment of Ubc9 is a prerequisite for
SUMO modification, and this occurs by direct recogni-
tion by Ubc9 of canonical SUMOylation sites. Ubc9 may
also be recruited via alternative interactions not involv-
ing its active site. In this case, SUMO modification often
occurs at multiple, noncanonical sites. Drp1 appears to
follow the latter pattern, given the multivalent interac-
tion between Drp1 and Ubc9 and the nonconsensus
nature of the modification sites. For example, Ubc9
interaction with the GTPase domain and the B domain
Figure 5. Preventing Drp1 SUMOylation does not alter its
translocation to mitochondria. HeLa cells were transfected
with Myc-tagged, WT Drp1 variant 3 or the 4 KR mutant form
that cannot be SUMOylated. A) Total cell lysates were immu-
noblotted for Myc. HSP60 levels were monitored on the same
immunoblot to ensure equal protein loading. B) Cells ex-
pressing WT or 4 KR mutant Drp1 were either left untreated
or else treated with staurosporine (STS) in the presence of
zVAD-fmk for 8 h. Mitochondria were isolated; equal protein
aliquots were resolved by SDS-PAGE, then immunoblotted for
Myc and HSP60.
Figure 6. Enhancement of SUMO modification of dominant-
negative Drp1. HEK-293 cells were transiently transfected with
pcDNA3-V5-Ubc9, pcDNA3-HA-SUMO3, and/or pcDNA3-V5-
His-Drp1 WT or pcDNA3-V5-His-Drp1 K38A, and CS2empty
vector. Protein extracts were obtained in the presence of 20 mM
NEM, processed as in Fig. 2A, and analyzed by immunoblotting.
Arrowheads indicate modified doublet; asterisk indicates un-
modified Drp1.
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may orient the active site of Ubc9 in proximity to the
lysine clusters within the B domain that are targeted for
SUMOylation. This is particularly attractive given the
extensive intra- and intermolecular interactions that
Drp1 engages in (16). Given that lysine 597 in the
second cluster resides within the sequence SKAEE, it is
possible that the interaction of Ubc9 with the B domain
involves in part the recognition of this sequence, which
has some of the features of the canonical SUMOylation
motif.
Recently, analyses of proteins that can interact with
Ubc9 in a similar manner, such as DAXX (63) or Kap1
(64), indicate that they act as SUMO E3 ligases by
serving as bridging partners to recruit Ubc9 to target
proteins. This is analogous to the mechanism of action
of ubiquitin E3 ligases of the Skp1-Cullin-F-Box com-
plex (SCF) type. Notably, DAXX, and Kap1 are
SUMOylated at multiple noncanonical sites, as is the
case for Drp1. It is therefore plausible that Drp1
recruitment of Ubc9 may facilitate the SUMOylation of
other proteins it interacts with during its normal func-
tions. Thus, the interaction of Drp1 with Ubc9 may
have functional consequences that extend beyond the
SUMOylation of Drp1 itself.
Our mutational analysis indicates that 8 lysines within
2 clusters in the B domain function as SUMO-acceptor
residues. Notably, four of these residues are located
within, or directly abutting, the differentially spliced
region of the B domain. Although no clear functional
difference has been detected between the three Drp1
variants, the reduced SUMO modification of variants 2
and 3 argue that differential SUMOylation may contrib-
ute to potential functional heterogeneity among variants.
During the review of this report, Zunino et al. (65)
indicated that a SUMO-modified Drp1 species corre-
sponding to the slow migrating band that we observe in
our experiments is modified in a cell cycle-dependent
manner. It will be interesting to determine whether the
Drp1 variants play different roles in this process.
Our identification of the major SUMO modification
sites in Drp1 is an essential step toward a direct assessment
of the role of this modification in Drp1 function. On the
basis of correlational data, it has been proposed that
during apoptosis, “locking” of SUMO1-modified Drp1 to
the mitochondrial membrane alters Drp1 cycling between
the cytoplasm and mitochondria in a Bax/Bak-dependent
manner prior to apoptotic fission as well as on onset of
mitosis (31, 66). Our data show that in cells ectopically
expressing a SUMOylation-deficient form of Drp1, the
basal and staurosporine-stimulated Drp1 translocation
to mitochondria is unaffected, indicating that loss of
SUMO modification in the ectopic Drp1 pool does not
lead to a dominant effect with respect to recruitment in
an unsynchronized population of actively growing cells.
SUMO modification, however, may influence other
aspects of Drp1 function downstream of mitochondrial
recruitment. Alternatively, a full assessment of the role
of Drp1 SUMOylation may require the replacement of
the endogenous complement of Drp1 with a non-
SUMOylatable form. SUMO modification also alters
the half-life of target proteins both in a positive or
negative direction. Although it has been proposed that
SUMOylation may stabilize Drp1 (28, 31, 32, 66), our
results indicate that disruption of SUMO acceptor
lysines in Drp1 affects neither protein stability nor ubiquiti-
nation of Drp1, arguing that Drp1 SUMOylation is not
directly linked to its degradation.
The GTPase activity of members of the dynamin
family of proteins is required for their ability to pro-
mote vacuolar endocytosis and mitochondrial fission
(19, 67, 68). Mutations in the GTP-binding (GTPase)
domain alter GTP binding and confer dominant-nega-
tive characteristics (67). A dominant form of Drp1
containing the K38A mutation, corresponding to the
K44A mutation in dynamin, is defective in GTP binding
and hydrolysis. Overexpression of this mutant alters
mitochondrial morphology by increasing tubular mito-
chondria at the center of the cell (19, 67, 69). Cellular
localization studies indicate that Drp1 K38A forms
aggregates in the cytoplasm that also likely contain WT
endogenous Drp1. Thus, an intact GTPase is critical for
Drp1 function and localization (16, 19, 70–74). Our
analysis of the SUMO modification of Drp1 K38A
indicates that the mutation leads to significantly en-
hanced SUMO3 modification. This observation argues
that the SUMO modification of Drp1 is linked to its
activity cycle. Since sedimentation experiments indicate
that the dominant-negative K38A Drp1 may be im-
paired in its ability to disassemble higher-order com-
plexes (16), SUMO modification may, therefore, be
part of a signal or mechanism for disassembly, a func-
tion reminiscent of the role of SUMOylation in the
disassembly of septins during cell division in S. cerevisiae
(75). The mechanism for enhanced SUMOylation of
this mutant, however, is unclear. In this regard, Zunino
et al. (65) have recently provided evidence that the
SUMO protease SENP5 translocates from the nucleoli
to the mitochondria at the onset of mitosis. In this
context, the enhanced SUMO3 modification of Drp1
K38A that we observe in our experiments may be a
consequence of its failure to translocate to mitochon-
dria where SENP5-catalyzed de-SUMOylation may nor-
mally take place. Notably, recent data indicate that,
similar to Drp1, dynamin-1 also associates with SUMO1
and Ubc9. Unlike Drp1, however, this interaction ap-
pears to be mediated by the GED domain (76, 77).
Although the in vivo SUMO acceptor lysines in dy-
namin have not been identified, it will be interesting to
examine whether SUMOylation of dynamin-1 is also
enhanced in the case of the analogous K44A dominant-
negative mutant.
Clearly, post-translational modifications such as phosphor-
ylation and ubiquitination regulate Drp1, and the mo-
lecular interplay between such modifications may be
important for Drp1 function (23, 24). It will therefore
be interesting to test whether phosphorylation of Drp1
alters its SUMOylation, or vice versa. Our identification
of the principal sites of SUMOylation in Drp1 provides
critical tools to define the biological importance of this
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post-translational modification and its relation to the
function of Drp1.
Recent advances in understanding the role of the
fission protein Drp1 in mitochondria function indicate
Drp1 may be a central regulator of devastating neuro-
degenerative disorders such as Parkinson’s disease,
Alzheimer’s disease and other neuropathies (15, 25,
78–81). In light of recent data linking SUMOylation
with the pathogenesis of neurodegenerative diseases
(82, 83), identifying signaling events and molecular
mechanisms regulating Drp1 post-translational modifi-
cations responsible for mitochondria homeostasis will
facilitate the identification of potential therapeutic
targets.
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